deferoxamine has been researched along with Nervous System Diseases in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 7.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
| "Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 3.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
| "The use of deferoxamine for iron chelation in transfusion-dependent thalassemia major is limited by serious neurotoxicity (hearing and vision loss)." | 3.68 | Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. ( Bentur, Y; Carley, H; Freedman, MH; Koren, G; Olivieri, N; Tesoro, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X | 1 |
| Qi, X | 1 |
| Li, H | 1 |
| Duan, Z | 1 |
| Wei, Y | 1 |
| Zhang, F | 1 |
| Tian, M | 1 |
| Ma, L | 1 |
| You, C | 1 |
| Chun, HJ | 1 |
| Kim, DW | 1 |
| Yi, HJ | 1 |
| Kim, YS | 1 |
| Kim, EH | 1 |
| Hwang, SJ | 1 |
| Jwa, CS | 1 |
| Lee, YK | 1 |
| Ryou, H | 1 |
| Helson, L | 1 |
| Braverman, S | 1 |
| Mangiardi, J | 1 |
| Yokel, RA | 1 |
| Regan, RF | 1 |
| Panter, SS | 1 |
| Kanwar, VS | 1 |
| Jenkins, JJ | 1 |
| Mandrell, BN | 1 |
| Furman, WL | 1 |
| Taher, A | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Inati, A | 1 |
| Neeman, R | 1 |
| Mourad, F | 1 |
| Davies, SC | 1 |
| Wonke, B | 1 |
| Bentur, Y | 1 |
| Koren, G | 1 |
| Tesoro, A | 1 |
| Carley, H | 1 |
| Olivieri, N | 1 |
| Freedman, MH | 1 |
| McLachlan, DR | 1 |
| Kruck, TP | 1 |
| VanBerkum, MF | 1 |
3 reviews available for deferoxamine and Nervous System Diseases
| Article | Year |
|---|---|
Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
Topics: Adult; Aluminum; Animals; Carboxylic Acids; Chelating Agents; Chelation Therapy; Child; Deferoxamine | 1994 |
The management of haemoglobinopathies.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc | 1991 |
Aluminum and neurodegenerative disease: therapeutic implications.
Topics: Aluminum; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Calcium; Deferoxamine; D | 1985 |
1 trial available for deferoxamine and Nervous System Diseases
| Article | Year |
|---|---|
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferiprone; De | 2001 |
6 other studies available for deferoxamine and Nervous System Diseases
| Article | Year |
|---|---|
Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
Topics: Animals; Brain Stem Hemorrhage, Traumatic; Chelating Agents; Collagenases; Deferoxamine; Heme Oxygen | 2019 |
Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Atrophy; Brain Edema; CD11b Antigen; Cerebral Hemorrhage; Deferoxamin | 2012 |
delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.
Topics: Aminolevulinic Acid; Cell Survival; Deferoxamine; Glioblastoma; Hemin; Humans; Nervous System Diseas | 1993 |
Neurotoxicity of hemoglobin in cortical cell culture.
Topics: Animals; Antioxidants; Cell Death; Cells, Cultured; Cerebral Cortex; Chromans; Culture Media; Defero | 1993 |
Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis.
Topics: Adolescent; Alum Compounds; Aluminum; Antidotes; Cystitis; Deferoxamine; Electroencephalography; Fem | 1996 |
Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deferoxamine; Dose | 1990 |